



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ramnarayan *et al.*
Serial No: 09/709,905
Filed: November 10, 2000
For: USE OF COMPUTATIONALLY DERIVED
PROTEIN STRUCTURES OF GENETIC
POLYMORPHISMS IN
PHARMACOGENOMICS FOR DRUG
DESIGN AND CLINICAL APPLICATIONS
Art Unit: Unassigned
Examiner: Unassigned

I hereby certify that this paper and the attached
papers are being deposited with the United States
Postal Service as first class mail in an envelope
addressed to:
Commissioner for Patents
Washington, D.C. 20231, on this date.

02/21/01
Date

Shelley M. Callagy

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is a Preliminary Amendment, an Information Disclosure Statement, and Forms PTO-1449 (10 pages) for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 50-1213, as stated below:

(X)

The Commissioner is hereby authorized to charge the fee for the Information Disclosure Statement and any other fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:

Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No.: 24737-1906C
Address all correspondence to:
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4250 Executive Square, 7th Floor
La Jolla, California 92037-9103
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com



#2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ramnarayan *et al.*

Serial No. 09/709,905

Filed: November 10, 2000

For: USE OF COMPUTATIONALLY DERIVED
PROTEIN STRUCTURES OF GENETIC
POLYMORPHISMS IN
PHARMACOGENOMICS FOR DRUG DESIGN
AND CLINICAL APPLICATIONS

Art Unit: Unassigned

Examiner: Unassigned

I hereby certify that this paper and the attached
papers are being deposited with the United States
Postal Service as first class mail in an envelope
addressed to:
Commissioner for Patents
Washington, D.C. 20231, on this date.

02/21/01
Date

Shelley M. Callagy

#2/A
Plunkett
4/27/02

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Preliminary to the examination of the above-captioned application, please
amend the application as follows:

IN THE TITLE:

Please amend the title as follows:

at page 1, line 2, please replace "AND" with —FOR DRUG DESIGN AND—;

IN THE SPECIFICATION:

Please amend the specification as follows:

at page 1, line 10, please replace "No." with —No. 09/704,362—;

at page 1, line 15, please replace "No." with —No. 09/704,362—;

at page 3, line 20, please replace "by the" with —by—;

at page 3, line 29, please replace "ethic" with —ethnic—;

at page 4, line 11, please replace "activity;" with —activity; and—;

at page 4, line 26, please replace "studies and" with —studies—;

at page 5, line 15, please replace "molecules" with —molecule—;